

## ORIGINAL ARTICLE

# The Oslo definitions for coeliac disease and related terms

Jonas F Ludvigsson,<sup>1,2</sup> Daniel A Leffler,<sup>3</sup> Julio C Bai,<sup>4</sup> Federico Biagi,<sup>5</sup> Alessio Fasano,<sup>6</sup> Peter H R Green,<sup>7</sup> Marios Hadjivassiliou,<sup>8</sup> Katri Kaukinen,<sup>9</sup> Ciaran P Kelly,<sup>3</sup> Jonathan N Leonard,<sup>10</sup> Knut Erik Aslaksen Lundin,<sup>11</sup> Joseph A Murray,<sup>12</sup> David S Sanders,<sup>13,14</sup> Marjorie M Walker,<sup>14</sup> Fabiana Zingone,<sup>15</sup> Carolina Ciacci<sup>16</sup>

► An additional appendix is published online only. To view this file please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2011-301346>).

For numbered affiliations see end of article.

## Correspondence to

Dr Daniel Leffler, Division of Gastroenterology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA; [dleffler@caregroup.harvard.edu](mailto:dleffler@caregroup.harvard.edu)

Revised 17 January 2012  
Accepted 20 January 2012  
Published Online First  
16 February 2012

## ABSTRACT

**Objective** The literature suggests a lack of consensus on the use of terms related to coeliac disease (CD) and gluten.

**Design** A multidisciplinary task force of 16 physicians from seven countries used the electronic database PubMed to review the literature for CD-related terms up to January 2011. Teams of physicians then suggested a definition for each term, followed by feedback of these definitions through a web survey on definitions, discussions during a meeting in Oslo and phone conferences. In addition to 'CD', the following descriptors of CD were evaluated (in alphabetical order):

asymptomatic, atypical, classical, latent, non-classical, overt, paediatric classical, potential, refractory, silent, subclinical, symptomatic, typical, CD serology, CD autoimmunity, genetically at risk of CD, dermatitis herpetiformis, gluten, gluten ataxia, gluten intolerance, gluten sensitivity and gliadin-specific antibodies.

**Results** CD was defined as 'a chronic small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals'. Classical CD was defined as 'CD presenting with signs and symptoms of malabsorption. Diarrhoea, steatorrhoea, weight loss or growth failure is required.' 'Gluten-related disorders' is the suggested umbrella term for all diseases triggered by gluten and the term gluten intolerance should not be used. Other definitions are presented in the paper.

**Conclusion** This paper presents the Oslo definitions for CD-related terms.

## INTRODUCTION

Coeliac disease (CD) is a chronic small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed people. Although symptoms and signs of CD have been recognised for more than 100 years, it was in the 1940s that the Dutch paediatrician Dicke established a link between the protein component of wheat (gluten) exposure and CD.<sup>1</sup> CD and related diseases are now common chronic diseases in children and adults, and increased diagnosis has led to a proliferation of research activities. As with many other chronic conditions, the boundaries of CD are not always clear, with the consequence that there is considerable confusion and a lack of consensus regarding diagnostic criteria of CD and related conditions.

## Significance of this study

### What is already known on this subject?

- There is a lack of consensus on the use of terms related to coeliac disease (CD) and gluten.
- Variability in the use of terminology has led to difficulty when comparing and evaluating clinical studies and research findings.

### What are the new findings?

- The panel reached agreement on the definition of terms related to CD and/or gluten currently in use in clinical practice and research.
- Some terms in current use should be abandoned because they are outdated or misleading.

### How might it impact on clinical practice in the foreseeable future?

- Uniform definitions for common terms relating to CD will improve communication among researchers, clinicians and the general public, and will ensure that research is conducted and reported in a consistent manner.

The first consensus definition of CD was published in *Acta Paediatrica* in 1970.<sup>2</sup> This publication defined CD as a permanent condition of gluten intolerance with mucosal flattening that reversed on a gluten-free diet (GFD) and then relapsed on re-introduction of gluten. Although the definition of CD has undergone minor changes since 1970,<sup>3,4</sup> consensus definitions have been restricted to CD. However, the scientific community has come to recognise that there is a spectrum of disorders related to gluten ingestion.

Due to a lack of common definitions for the spectrum of terms and disorders related to CD, a multidisciplinary task force of 16 physicians from seven countries with particular expertise in diagnosis and treatment of CD proposes the following definitions for the variety of vague and often confusing terms currently in use in the literature. These definitions are based on thorough literature reviews (table 1), a discussion in Oslo at the 14th International Coeliac Disease Symposium in June 2011, and agreement on consensus statements by a web survey and phone conferences. We refer to our definitions as the 'Oslo definitions'.



► <http://dx.doi.org/10.1136/gutjnl-2012-302613>

## Coeliac disease

**Table 1** Terms evaluated for this review

| Term                           | PubMed hits until January 2011* |
|--------------------------------|---------------------------------|
| <b>Defined</b>                 |                                 |
| Coeliac disease (CD)†          | 14 843                          |
| Asymptomatic CD                | 39                              |
| Classical CD                   | 10                              |
| Paediatric classical CD†       | —                               |
| Non-classical                  | 3                               |
| Potential CD                   | 33                              |
| Refractory CD                  | 109                             |
| Subclinical CD                 | 43                              |
| Symptomatic CD                 | 26                              |
| CD autoimmunity‡               | 16                              |
| Genetically at risk of CD†     | —                               |
| Dermatitis herpetiformis†      | 2759                            |
| Gluten†                        | 8879                            |
| Gluten ataxia                  | 28                              |
| Non-coeliac gluten sensitivity | 85                              |
| Gliadin-specific antibodies§   | 5                               |
| Overt CD                       | 10                              |
| Gluten-related disorders       | 12                              |
| <b>Discouraged</b>             |                                 |
| Atypical CD                    | 13                              |
| Latent CD                      | 78                              |
| Typical CD                     | 11                              |
| Gluten intolerance             | 244                             |
| Gluten sensitivity             | 241                             |
| Silent CD                      | 80                              |
| CD serology¶                   | 15                              |

\*We searched PubMed for the period 1 January 1900 to 31 January 2011. Individual authors then examined papers deemed most relevant. When the phrase 'coeliac disease' is part of the definition, we searched PubMed for the relevant term *and* coeliac disease (British and American spelling). For example, 'silent coeliac disease' [All Fields] OR 'silent coeliac disease' [All Fields] AND ('1900/01/01' [PDAT]: '2011/01/31' [PDAT]).

†For these terms, our literature review was entirely based on expert consensus of the literature because it was beyond the scope of this paper to review all papers identified through PubMed (or as in the case of 'paediatric classical CD' there were no hits).

‡We searched for 'coeliac disease autoimmunity' and 'coeliac autoimmunity' (British and American spelling).

§A search for 'gluten and antibodies' yielded 2529 hits.

¶Although we discourage the use of the term 'CD serology', we have provided a definition for this term.

The purpose of our recommended definitions is to create a foundation for clinical management and research. Clear definitions will allow more efficient and generalisable advances in CD research relating to aetiology, incidence, prevalence, complications and treatment of patients with CD and other gluten-related disorders.

## METHODS

### Task force constitution

Members of this collaborative effort were invited to participate by two of the authors (DAL and CC). The constitution of the group reflects the wide variety of disciplines to which CD may present in practice: gastroenterology, histopathology, paediatrics, neurology and dermatology. Members of the task force were from Sweden, the USA, Argentina, Italy, the UK, Finland and Norway. Four of the five physicians from the USA had trained elsewhere (two in Ireland, one in Australia and one in Italy).

### Literature review

Teams of three or four physicians were assigned between one and four CD-related terms. Each team carried out a literature search (table 1) of the entire electronic database PubMed up to January 2011 using the terms as key words. These terms

included CD and the following descriptors of CD: asymptomatic, atypical, classical, latent, non-classical, overt, paediatric classical, potential, refractory, silent, subclinical, symptomatic, typical, CD serology, CD autoimmunity, genetically at risk of CD, dermatitis herpetiformis, gluten, gluten ataxia, gluten intolerance, gluten sensitivity and gliadin-specific antibodies.

The literature review was mostly restricted to original papers and reviews. Most papers had been published after 1990. The teams then suggested definitions for each term.

### Web survey

A web survey was then conducted and all suggested definitions were listed and subjected to peer review (online appendix).

Comments and feedback from the web survey were taken into account when creating a second set of definitions.

### Discussions and phone meetings

The revised definitions and appending comments were then discussed in Oslo at the 14th International CD Symposium in June 2011. This discussion was followed by two phone conferences in which the remaining definitions were discussed until consensus was achieved. We did not grade the evidence underlying each definition because that was not the purpose of the task force and this review did not deal with clinical management. For the convenience of readers, each definition given in the Results section below is followed by a short literature review of each term. Two terms were added after the initial web survey and the meeting in Oslo: 'dermatitis herpetiformis' and 'CD autoimmunity', which were discussed through email.

## RESULTS

### Coeliac disease

Coeliac disease is a chronic small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals.

CD is triggered by the ingestion of gluten (definition below), the protein component of wheat, rye, barley, but not oats.<sup>5,6</sup> Such exposure results in a variable degree of intestinal damage.<sup>7</sup> In most patients with CD, the enteropathy will reverse on a GFD.<sup>2-4</sup> According to the suggested definition, CD is a chronic disease, but as the discussion of the terms potential CD and latent CD will show, there are reports of transient CD.<sup>8</sup>

Although CD is the most common cause of enteropathy in the western world and enteropathy is a prerequisite for CD, it should be noted that other diseases may cause small intestinal inflammation but do not qualify as CD.<sup>9</sup> Typically, the inflammation in CD includes an increased intraepithelial lymphocyte (IEL) count, most often >25/100 cells.<sup>9,10</sup> Another feature of CD is that it incorporates an adaptive T-cell-mediated response (to gluten) and that it occurs in people who are DQ2–DQ8 positive.<sup>11,12</sup> Increasingly, the presence of specific endomysial antibodies (EMA, also called AEA), anti-tissue transglutaminase antibodies (TTG, a-tTG, TTA), and/or deamidated antigliadin antibodies (DGP) plays an important role in the serological work-up for CD. These antibodies strongly support the diagnosis of CD, but by themselves are not confirmatory.

To confirm a diagnosis of CD, biopsies of the duodenum must be taken when patients are on a gluten-containing diet. Consensus states four to six biopsies are necessary for diagnosis,<sup>13</sup> including from the duodenal bulb.<sup>14,15</sup>

Three histological classifications of CD are used: Marsh,<sup>7</sup> Marsh–Oberhuber<sup>16</sup> and Corazza.<sup>10</sup> A comparison of these classifications is shown in table 2.

**Table 2** Comparison of histopathological classifications

| Morphology of duodenal mucosal biopsy  | Classification   |  |   |
|--|--|--|---|
|  | Marsh* <sup>7</sup>  | Marsh-Oberhuber <sup>16</sup>  | Corazza <sup>10</sup>                               |
| Normal   | Type 0   | Type 0   | Normal  |
| Normal architecture and increased intraepithelial lymphocytes $\geq 25/100$ enterocytes                                      | Type 0   | Type 0   | Grade A   |
| Normal architecture and increased intraepithelial lymphocytes $\geq 40/100$ enterocytes                                      | Type 1   | Type 1   | Grade A   |
| Normal architecture and increased intraepithelial lymphocytes $\geq 40/100$ enterocytes with crypt hyperplasia               | Type 2   | Type 2   | Grade A   |
| Partial villous atrophy and increased intraepithelial lymphocytes $\geq 40/\geq 25/100$ enterocytes                          | Type 2 hyperplastic lesion<br>Crypt hyperplasia, increased crypt height and influx of inflammatory cells | Type 3 destructive<br><br>Type 3a partial villous atrophy;<br>villi blunt and shortened with a villous:crypt ratio, 1:1<br>Type 3b subtotal villous atrophy;<br>villi atrophic but still separate and recognisable | Grade B1 atrophic, villous to crypt ratio is $<3:1$ |
| Total villous atrophy intraepithelial lymphocytes $\geq 40/\geq 25/100$ enterocytes  | Type 3 destructive severe inflammation, flat villi; hyperplastic crypts                                  | Type 3c total villous atrophy; villi rudimentary or absent; mucosa resembles colonic mucosa  | Grade B2 atrophic, villi are no longer detectable   |
| Atrophic hypoplastic lesion: flat mucosa, normal crypt height, no inflammation with normal intraepithelial lymphocyte counts | No equivalent  | Type 4   | No equivalent                                       |

\*Marsh initially explored the association of mucosal damage with a progressively increased gluten intake in treated patients with celiac disease. This staging has since been used as a classification.

Historically, CD has been equivalent to sprue, coeliac sprue, gluten-sensitive enteropathy and gluten intolerance. In the past the terms non-tropical sprue and idiopathic steatorrhoea were used.<sup>17 18</sup> None of these terms are currently recommended.

### Gluten

Gluten is the commonly used term for the complex of water insoluble proteins from wheat, rye and barley that are harmful to patients with CD.

The major seed proteins in cereals are the alcohol-soluble prolamins, a complex group of alcohol-soluble polypeptides that make up about half of the protein in the mature grain. The term gluten indicates a broad group of prolamins (gliadins and glutenins) found in wheat. Other prolamins showing similar immunogenic properties are also found in rye (secalins), barley (hordeins) and other closely related grains.<sup>13 19</sup> The major prolamins of the more distantly related maize (zeins) seem to have evolved independently and show no harmful effects in patients with CD. Oats have also been shown to be non-immunogenic in most patients with CD.<sup>20</sup> A GFD usually indicates a diet free from wheat, rye, barley, triticale, kamut and spelt.

Gluten is poorly digested in the human intestine with or without CD. Gluten peptides cross intact into the submucosa of the small intestine. In the submucosa of the small intestine the human enzyme transglutaminase 2 also referred to as tissue transglutaminase (tTG) deamidates gluten peptides, which allows for high-affinity binding to human leucocyte antigen (HLA) DQ2 and HLA DQ8 molecules, subsequently triggering an inflammatory reaction in patients with CD.<sup>12</sup>

Gluten content in food is regulated by the *Codex Alimentarius* (<http://www.codexalimentarius.net>). This codex (CODEX STAN 118–1979 revised in 2008) states that gluten-free foods are foods or ingredients naturally free of gluten, in which the measured gluten level is  $\leq 20$  mg/kg in total, or processed to  $<100$  mg/kg. According to the current Codex, foods meeting these criteria may be labelled as a 'gluten-free food'.

### Asymptomatic CD

Asymptomatic CD is not accompanied by symptoms even in response to direct questioning at initial diagnosis.

Individuals with asymptomatic CD do not manifest any symptoms commonly associated with CD and have no symptoms that respond to gluten withdrawal, even in response to direct questioning. These patients are often diagnosed through testing of populations enrolled in screening programmes or in case-finding strategies for detecting CD in patients with disorders that are associated with a high risk for CD.<sup>21–33</sup> Many of these patients suffer from decreased quality of life. Sometimes minor symptoms (eg, fatigue) are only recognised after the introduction of a GFD;<sup>34</sup> such patients do not suffer from true asymptomatic CD and should be reclassified as having subclinical CD.

### Typical CD

Historically, typical CD has denoted a gluten-induced enteropathy presenting with signs or symptoms of malabsorption/global malabsorption (such as diarrhoea or malnutrition) or a malabsorption syndrome (indicated by weight loss, steatorrhoea and oedema secondary to hypoalbuminemia). The above use is questionable in that the clinical presentation of CD has changed over time,<sup>35–37</sup> and the word 'typical' implies that this form is the most frequently encountered form of CD. In contrast, many current patients have symptoms such as anaemia,<sup>38–40</sup> fatigue<sup>41 42</sup> and abdominal pain.<sup>43</sup>

We therefore discourage the use of the term typical CD.

### Atypical CD

Atypical CD can only be used in reference to typical CD. Historically, atypical CD has been used to describe patients with gluten-induced enteropathy who have no weight loss but present with any of the following symptoms or signs: gastrointestinal symptoms,<sup>44</sup> including symptoms suggestive of irritable bowel syndrome<sup>45 46</sup> and liver dysfunction<sup>47 48</sup>; extraintestinal manifestations, such as metabolic disease/

## Coeliac disease

symptoms (failure to thrive, thyroid dysfunction (hypo/hyper))<sup>49–50</sup>; neurologic findings,<sup>51–53</sup> including depression<sup>54</sup> and gluten ataxia<sup>55</sup>; reproductive disease,<sup>56–58</sup> including abnormalities in menarche and menopause<sup>58–59</sup>; oral/cutaneous disease,<sup>60–64</sup> including dermatitis herpetiformis (DH);<sup>65</sup> and skeletal findings.<sup>66</sup> Atypical CD has also been used to denote patients with a gluten-induced enteropathy and significant nutritional deficiencies (such as iron deficiency). We argue that the term atypical CD should not be used. Some patients previously described as having atypical CD may fulfil the requirements for non-classical CD (see below).

### Classical CD

Classical CD presents with signs and symptoms of malabsorption. Diarrhoea, steatorrhoea, weight loss or growth failure is required.

Classical and typical CD have traditionally been similar concepts defining the presence of a gluten-induced enteropathy presenting with diarrhoea, malnutrition or a malabsorption syndrome (indicated by weight loss, steatorrhoea and oedema secondary to hypoalbuminemia).<sup>7–67–74</sup> While recognising that these symptoms are not specific to CD, we encourage the use of classical CD, as defined above, because the term 'classical' does not imply that this type of CD is more common than CD without clinical malabsorption. Examples of classical CD are patients with diarrhoea and weight loss but also patients with weight loss and anaemia.

Paediatric classical CD is the paediatric equivalent of classical CD. These children are often characterised by failure to thrive, diarrhoea, muscle wasting, poor appetite and abdominal distension.<sup>75–79</sup> Many children with classical CD and malabsorption also show signs of emotional distress ('change of mood') and lethargy.<sup>72</sup>

### Non-classical CD

Non-classical CD presents without signs and symptoms of malabsorption.

In non-classical CD the patient does not suffer from malabsorption (eg, a patient with constipation and abdominal pain but no malabsorption). Patients with monosymptomatic disease (other than diarrhoea or steatorrhoea) usually have non-classical CD.

### Silent CD

Silent CD is equivalent to asymptomatic CD. We discourage the use of the term silent CD.

### Subclinical CD

Subclinical CD is below the threshold of clinical detection.

The term subclinical has often been used to denote silent CD<sup>80–82</sup> or patients with CD and extraintestinal symptoms (and no gastrointestinal symptoms).<sup>83</sup> The term has also been used for patients with CD who have clinical or laboratory signs (iron deficiency anaemia, abnormalities in liver function tests, enamel defects, incidental endoscopic features, osteoporosis, etc) but no symptoms.<sup>84</sup>

As understanding of CD has advanced, new disease associations have been regularly found and populations tested for CD have changed in response. For this reason, what is 'subclinical' has changed over time. To provide a stable definition, we specified subclinical CD to be disease that is below the threshold of clinical detection without signs or symptoms sufficient to trigger CD testing in routine practice.

### Symptomatic CD

Symptomatic CD is characterised by clinically evident gastrointestinal and/or extraintestinal symptoms attributable to gluten intake.

The clinical manifestations of CD vary from none (asymptomatic CD) to a wide spectrum of symptoms. The vast majority of authors describing symptomatic CD do not distinguish between CD with gastrointestinal symptoms and CD with extraintestinal symptoms.<sup>85–98</sup>

What was previously called overt CD should be considered part of symptomatic CD.

### Overt CD

Overt CD has most often been characterised by clinically evident gluten-related symptoms, either gastrointestinal (dyspepsia, diarrhoea and bloating) or extraintestinal (neurological symptoms and fatigue).<sup>99–100</sup> We recommend that the term overt CD should not be used; symptomatic CD is the preferred term.

### Refractory CD

Refractory CD (RCD) consists of persistent or recurrent malabsorptive symptoms and signs with villous atrophy (VA) despite a strict GFD for more than 12 months.

Although definitions of RCD differ slightly,<sup>101–118</sup> most expert-opinion-based definitions include persistence or recurrence of malabsorptive symptoms and signs (eg, diarrhoea, abdominal pain, involuntary loss of weight, low haemoglobin and hypoalbuminemia) associated with persistent or recurrent VA despite a strict GFD for more than 12 months (or severe persistent symptoms independently of the duration of GFD) in the absence of other causes of VA or malignant complications<sup>119</sup> and after the confirmation of the initial diagnosis of CD.

Generally, most patients are negative for EMA and TTG at the time of RCD diagnosis, but the presence of persisting elevated titres of circulating EMA and/or TTG does not necessarily rule out RCD, though this should lead to questions about dietary adherence. In all cases, a careful dietary interview should be performed to exclude gluten exposure before diagnosing RCD.<sup>120</sup> Not all dietary non-responsive CD is RCD.<sup>121–123</sup>

RCD is divided into two categories<sup>111–115</sup>: type I, in which a normal IEL phenotype is found; and type II, in which there is a clonal expansion of an aberrant IEL population. The abnormal phenotype is supported by loss of normal surface markers CD3, CD4 and CD8 with preserved expression of intracytoplasmic CD3 (CD3ε) in >50% of IELs as evaluated by immunohistochemistry or >20% as determined by flow cytometry, and by detection of clonal rearrangement of T-cell receptor chains (γ or δ) by PCR.<sup>104–107–108–115–116</sup>

### Latent CD

The literature reveals at least five definitions of latent CD: positive CD serology in patients with normal mucosa or absence of VA;<sup>124–129</sup> and normal mucosa in patients who are on a gluten-containing diet, but have had an earlier or will have a later flat mucosa when they eat gluten.<sup>130–134</sup> To some physicians latent CD is simply equivalent to undiagnosed CD,<sup>135–136</sup> whereas others refer to latent CD as CD preceded by another autoimmune disease (eg, type I diabetes or thyroid disease). Finally, latent CD is sometimes used to denote normal mucosa with non-serological abnormalities, such as an increased number of γ or δ cells, or increased mucosal permeability.<sup>137</sup> Considering that the terms potential CD and latent CD have

often been used interchangeably, resulting in confusion, we discourage the use of the term latent CD.

### Potential CD

Potential CD relates to people with a normal small intestinal mucosa who are at increased risk of developing CD as indicated by positive CD serology.

Potential CD is also often used with different meanings. For some, potential CD means that the patient has an increased number of IELs in the villi<sup>138</sup> or increased expression of  $\gamma$  or  $\delta$  cells.<sup>139</sup> To others, potential CD describes people with normal mucosa but positive CD serology.<sup>140 141</sup> Adding to this is the suggestion by Ferguson *et al* that all first-degree relatives to patients with CD have potential CD.<sup>142</sup>

We recommend that the term potential CD be used for people with normal small intestinal mucosa who are at increased risk of developing CD as indicated by positive CD serology. A difficulty in the definition of this group is variability in the adequacy of the biopsies that were taken to exclude the diagnosis of active CD, especially with the current knowledge that at least four biopsies need to be taken<sup>143</sup> and the bulb may be the only location of VA.<sup>15</sup>

### CD autoimmunity

CD autoimmunity relates to increased TTG or EMA on at least two occasions when status of the biopsy is not known. If the biopsy is positive, then this is CD, if the biopsy is negative than this is potential CD.

The term 'coeliac disease autoimmunity' or 'coeliac autoimmunity' has been used to describe: individuals with positive TTG,<sup>144–147</sup> positive EMA,<sup>148</sup> positive EMA with positive/borderline TTG,<sup>149</sup> positive TTG on at least two occasions,<sup>150</sup> and positive TTG on two occasions or a positive small bowel biopsy after only a single positive TTG.<sup>151</sup>

We defined CD autoimmunity as positive TTG or EMA on at least two occasions. In a clinical setting this will lead to a small intestinal biopsy, and patients can then be classified as either CD (positive biopsy) or potential CD (negative biopsy), but in a research setting there are circumstances when small intestinal biopsy has not been performed. The term CD autoimmunity should then be used. When TTG or EMA has only been tested on one occasion, it is preferable to refer to patients as TTG positive or EMA positive.

### Genetically at risk of CD

Family members of patients with CD that test positive for HLA DQ2 and/or DQ8 are genetically at risk of CD.

CD is a multifactorial condition with unparalleled evidence of the pivotal role of HLA-DQA1\*05-DQB1\*02 (DQ2) and DQA1\*03-DQB1\*0302 (DQ8) in disease predisposition.<sup>152 153</sup> DQ2 and DQ8 are major risk factors carried by almost all patients with CD. Interestingly, when carried in *trans* on DR5/DR7 (ie, DQA1\*05-DQB1\*0301/DQA1\*0201-DQB1\*02) or DR3/DR7 (ie, DQA1\*05-DQB1\*02/DQA1\*0201-DQB1\*02) genotypes, the risk of CD in southern Europeans is higher than when the alleles are carried in *cis* on DR3 (ie, DQA1\*05-DQB1\*02) alone, suggesting that additional factors in the region may be influencing disease propensity.

Non-HLA genes together contribute more to genetic susceptibility (approximately 65%) than the HLA genes (the remaining 35%), but the contribution from each single, predisposing non-HLA gene appears to be modest.<sup>154</sup>

At the moment, the concept of genetically at risk for CD should be limited to family members (of patients with CD) who

test positive for HLA-DQ2 or HLA-DQ8, with the understanding that the risk varies between 2% and 20%, depending on the degree of the relative with CD and the number of copies of HLA-DQ2 genes. However, people who harbour these genes are at risk of developing CD.

### Gluten intolerance

The term gluten intolerance has been used as a synonym of CD and to indicate that a patient experiences a clinical improvement after starting a GFD, even when they do not have CD.<sup>8 76 122 155–166</sup> However, we believe the term gluten intolerance is non-specific and carries inherent weaknesses and contradictions. Although gluten intolerance could be a consequence of poor digestion, it could also be the effect of some lectin-like properties of gluten or foods generated from gluten that cause gastrointestinal upset. Another problem is that gluten intolerance may not truly reflect intolerance to gluten but to other wheat components.<sup>156</sup> Because of these contradictions, we recommend that the term gluten intolerance should not be used and that gluten-related disorders be used instead.

### Gluten-related disorders

Gluten-related disorders is a term used to describe all conditions related to gluten.

We recommend that this term is used to describe all conditions related to gluten. This may include disorders such as gluten ataxia, DH, non-coeliac gluten sensitivity (NCGS) and CD.<sup>115 167 168</sup>

### Gluten sensitivity

In some papers the term gluten sensitivity is used synonymously with CD.<sup>7</sup> Other papers used the concept of gluten sensitivity as an umbrella term to include CD and other conditions related to gluten ingestion, such as DH,<sup>169</sup> gluten ataxia<sup>170</sup> and NCGS.<sup>156</sup> Most recently,<sup>157 171–174</sup> several authors employed the term gluten sensitivity to describe a condition in which symptoms are triggered by gluten ingestion, in the absence of TTG or EMA antibodies and enteropathy, with variable HLA status and variable anti-gliadin (AGA) presence. It is important to distinguish CD from less well characterised diseases related to gluten ingestion. We therefore recommend that the term gluten sensitivity should not be used and that NCGS be used instead.

### Non-coeliac gluten sensitivity

The term NCGS relates to one or more of a variety of immunological, morphological or symptomatic manifestations that are precipitated by the ingestion of gluten in people in whom CD has been excluded.

NCGS is a condition in which gluten ingestion leads to morphological or symptomatic manifestations despite the absence of CD.<sup>172–176</sup> As opposed to CD, NCGS may show signs of an activated innate immune response but without the enteropathy, elevations in tTG, EMA or DGP antibodies, and increased mucosal permeability characteristic of CD.<sup>173</sup> Recently, in a double-blind randomised trial, Biesiekierski *et al* showed that patients with NCGS truly develop symptoms when eating gluten.<sup>156</sup> It is unclear at this time what components of grains trigger symptoms in people with NCGS and whether some populations of patients with NCGS have subtle small intestinal morphological changes. While there is currently no standard diagnostic approach to NCGS, systematic evaluation should be conducted, including exclusion of CD and other inflammatory disorders.

## Coeliac disease

### Gliadin-specific antibodies

These are AGAs of IgA and IgG subclass recognising the gliadin moiety of wheat. Antibodies recognising native gluten are now rarely used for diagnostic purposes because they lack general specificity. Antibodies recognising DGP demonstrate high specificity and sensitivity. They can also be used for measurement of gluten in foodstuffs.

Use of the term gliadin-specific antibodies generally refers to antibodies directed against the gliadin moiety of wheat prolamins. The following four aspects of these antibodies are relevant to the spectrum of gluten-induced disease.

### Diagnostic value

After introduction in the 1980s, IgA antibodies against wheat gliadin (AGAs) served as the best serological test for CD for some years.<sup>177 178</sup> However, the low positive predictive value<sup>179</sup> meant that this test has since been abandoned for the investigation of CD,<sup>13 179</sup> except for in children younger than 18 months, in whom IgA AGA seems to have high sensitivity.<sup>180</sup> Recently, assays for IgA and IgG antibodies against DGP have been introduced<sup>181</sup> and perform similarly to TTG-based tests.<sup>179</sup>

### Increased gut permeability

Elevated levels of AGAs have also been used for the investigation of possible increased gut permeability, but this use in clinical practice lacks a strong scientific background.

### Disorders beyond the classical enteropathy

AGAs are also relevant to gluten-induced disorders beyond the classical enteropathy. The most well known example is gluten ataxia. Patients with this disorder may have CD or only elevated levels of IgA or IgG AGAs<sup>55</sup> (see gluten ataxia).

### Measurement of gluten in foods

Gluten-specific antibodies have a clear role in the food industry in that they are indispensable for measurement of gluten in foods. More recently, an assay using a monoclonal antibody recognising a major coeliac toxic epitope has been developed.<sup>182</sup> This assay is now the preferred method for gluten analysis in food.<sup>183</sup>

### Coeliac disease serology

Coeliac disease serology is a term that includes endomysium, transglutaminase, deamidated gliadin antibodies, and in small children also gliadin antibodies for the assessment of CD.

Since the introduction of AGAs, antibodies have become an important means to diagnose CD. Serological testing has been used routinely in the investigation of CD since the 1980s. Whereas AGA tests were common in the 1980s and 1990s,<sup>184</sup> laboratories have since gradually shifted to EMA and TTG tests.<sup>185–187</sup> In most patient groups with suspected CD, EMA and TTG tests have a higher sensitivity and specificity than the AGA test.<sup>188</sup> We defined CD serology as an all-encompassing term that includes all available tests which have been shown in clinical studies to be sensitive for assessment of CD. Accordingly, we discourage the use of the term CD serology in that it is preferable to specify the antibody tests used because sensitivity and specificity differ substantially. We have nevertheless suggested a definition of this term because it is extensively used.

### Gluten ataxia

Gluten ataxia can be defined as idiopathic sporadic ataxia and positive serum anti-gliadin antibodies even in the absence of duodenal enteropathy.

Gluten ataxia is one of a number of neurological manifestations attributed to CD. Defining criteria for gluten ataxia<sup>170 189 190</sup> include otherwise idiopathic sporadic ataxia in association with positive AGA with or without enteropathy on duodenal biopsy. Most reports (22 of 35 reports) after 1998 have used the same definition, that is, idiopathic sporadic ataxia with positive AGA (IgG or IgA, or both). However, a number of reports refer to patients with established CD (13 of 35 reports) without always providing serological information on these patients other than stating that the patient had CD (taken to imply the presence of enteropathy).<sup>170 191–199</sup>

One report examined the presence of IgA deposits on duodenal biopsies and found that all 10 patients with gluten ataxia (without enteropathy) had such deposits.<sup>195</sup> One study has identified a novel transglutaminase (TTG6) as a potential new serological marker for gluten ataxia,<sup>192</sup> but currently the most appropriate definition for gluten ataxia remains that of idiopathic sporadic ataxia with positive AGA.

### Dermatitis herpetiformis

DH is a cutaneous manifestation of small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten. It is characterised by herpetiform clusters of pruritic urticated papules and vesicles on the skin, especially on the elbows, buttocks and knees, and IgA deposits in the dermal papillae. DH responds to a GFD.

DH is characterised by the presence of IgA deposits in the skin,<sup>200–202</sup> is strongly linked to an immune-mediated enteropathy precipitated by gluten,<sup>65 203–205</sup> and responds to a GFD.<sup>206–209</sup> A study from the USA in 1992 documented a prevalence of 11.2 per 100 000 people and an incidence of 0.98 per 100 000 people per year.<sup>210</sup> These rates are comparable to earlier studies of prevalence of DH in northern Europe.<sup>205</sup>

VA will be revealed by a single intestinal biopsy in two-thirds of patients, and by multiple biopsies in 95%. The enteropathy is variable in severity, but even in the presence of normal villous architecture, elevated levels of  $\gamma\delta$  T lymphocytes in the intestinal mucosa, elevated IEL counts and induction of VA are noted on gluten challenge, and these patients are very likely to reflect the entire spectrum of histological and clinical CD in adults.<sup>65 211</sup> The association with HLA is the same as in CD: 90% of patients have HLA DQ2 and almost all the remainder have HLA DQ8.<sup>212</sup> The skin lesions clear with gluten withdrawal but may also require treatment by the neutrophil inhibitor dapsone.<sup>207 208 213</sup> In the long term, adherence to a strict GFD shows 47% of patients can stop drug treatment completely; however 15% will not be able to reduce the dose of dapsone.<sup>214</sup>

### DISCUSSION

This review was based on PubMed literature searches and expert meetings. We aimed to define key concepts relevant to CD and related disorders. The character of the current paper implies that we did not pool any data or use any statistical tools. Instead, we assembled an international team of recognised experts in CD research, discussed definitions and tried to reach a consensus. This approach is similar to that of previous papers on definitions of CD.<sup>2–4</sup> As opposed to previous studies,<sup>2–4</sup> however, we did not limit ourselves to 'CD only' but defined a large number of concepts. In addition, we provide guidance to the scientific and clinical community as to which terms should be used and which should be abandoned.

Overall, we evaluated more than 300 papers in detail and all authors participated in the discussion leading to consensus

definitions. We tried to avoid cumbersome definitions and have mostly avoided the inclusion of specific techniques, antibodies and measurements or units in these definitions. Cumbersome definitions are rarely used in practice and because of the progress in the CD research field, statements on specific tests may rapidly become obsolete.

Our research team was multidisciplinary and was composed of specialists from gastroenterology, pathology, paediatrics, neurology and dermatology. We hope that our definitions will be acceptable to all specialties dealing with CD and gluten-related disorders and anticipate that they will facilitate both research and clinical management of patients with these disorders.

#### Author affiliations

- <sup>1</sup>Department of Paediatrics, Örebro University Hospital, Örebro, Sweden
- <sup>2</sup>Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
- <sup>3</sup>Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
- <sup>4</sup>Department of Medicine, Dr C. Bonorino Udaondo Gastroenterology Hospital, Del Salvador University, Buenos Aires, Argentina
- <sup>5</sup>Coeliac Centre/First Department of Internal Medicine, University of Pavia, Pavia, Italy
- <sup>6</sup>Center for Coeliac Research, University of Maryland School of Medicine, Baltimore, Maryland, USA
- <sup>7</sup>Coeliac Disease Center, Columbia University, New York, New York, USA
- <sup>8</sup>Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK
- <sup>9</sup>School of Medicine, FIN-33014 University of Tampere, Tampere, Finland
- <sup>10</sup>Department of Dermatology, Imperial College NHS Healthcare Trust, St Mary's Hospital, London, UK
- <sup>11</sup>Department of Gastroenterology and Centre for Immune Regulation, Oslo University Hospital, Oslo, Norway
- <sup>12</sup>Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
- <sup>13</sup>Gastroenterology and Liver Unit, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK
- <sup>14</sup>Centre for Pathology, Faculty of Medicine, Imperial College, St Mary's Hospital, London, UK
- <sup>15</sup>Department of Clinical and Experimental Medicine, Federico II University of Naples, Naples, Italy
- <sup>16</sup>Department of Gastroenterology, University of Salerno, Salerno, Italy

**Contributors** CC and DAL initiated the study. JFL coordinated the project, conducted the web survey on coeliac disease definitions, and wrote the first draft of the paper. All authors contributed to the literature searches, contributed to the writing of the article, and approved the final version of the article.

**Funding** JFL was supported by the Swedish Research Council (522-2A09-195) and the Swedish Society of Medicine while writing the draft of this paper. DAL is supported by the National Institute of Health (NIH DK1042103881). None of the funding organisations had any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review, or approval of the article.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** All data are available on request.

#### REFERENCES

1. **van Berge-Henegouwen GP**, Mulder CJ. Pioneer in the gluten free diet: Willem-Karel Dicke 1905–1962, over 50 years of gluten free diet. *Gut* 1993;**34**:1473–5.
2. **Meeuwisse GW**. Round table discussion. Diagnostic criteria in coeliac disease. *Acta Paediatr* 1970;**59**:461–3.
3. **McNeish AS**, Harms HK, Rey J, *et al*. The diagnosis of coeliac disease. A commentary on the current practices of members of the European Society for Paediatric Gastroenterology and Nutrition (ESPGAN). *Arch Dis Child* 1979;**54**:783–6.
4. **Anon**. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. *Arch Dis Child* 1990;**65**:909–11.
5. **Janatuinen EK**, Pikkarainen PH, Kempainen TA, *et al*. A comparison of diets with and without oats in adults with coeliac disease. *N Engl J Med* 1995;**333**:1033–7.
6. **Vader LW**, de Ru A, van der Wal Y, *et al*. Specificity of tissue transglutaminase explains cereal toxicity in coeliac disease. *J Exp Med* 2002;**195**:643–9.
7. **Marsh MN**. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). *Gastroenterology* 1992;**102**:330–54.
8. **Walker-Smith JA**. Transient gluten intolerance. *Arch Dis Child* 1996;**74**:183–4.
9. **Walker MM**, Murray JA, Ronkainen J, *et al*. Detection of coeliac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study. *Gastroenterology* 2010;**139**:112–19.
10. **Corazza GR**, Villanacci V, Zambelli C, *et al*. Comparison of the interobserver reproducibility with different histologic criteria used in coeliac disease. *Clin Gastroenterol Hepatol* 2007;**5**:838–43.
11. **Lundin KE**, Scott H, Hansen T, *et al*. Gliadin-specific, HLA-DQ(alpha 1\*0501, beta 1\*0201) restricted T cells isolated from the small intestinal mucosa of coeliac disease patients. *J Exp Med* 1993;**178**:187–96.
12. **Molberg O**, McAdam SN, Korner R, *et al*. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in coeliac disease. *Nat Med* 1998;**4**:713–17. [published erratum appears in *Nat Med* 1998;**4**:974].
13. **Rostom A**, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of coeliac disease. *Gastroenterology* 2006;**131**:1981–2002.
14. **Hopper AD**, Cross SS, Sanders DS. Patchy villous atrophy in adult patients with suspected gluten-sensitive enteropathy: is a multiple duodenal biopsy strategy appropriate? *Endoscopy* 2008;**40**:219–24.
15. **Gonzalez S**, Gupta A, Cheng J, *et al*. Prospective study of the role of duodenal bulb biopsies in the diagnosis of coeliac disease. *Gastrointest Endosc* 2010;**72**:758–65.
16. **Oberhuber G**, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. *Eur J Gastroenterol Hepatol* 1999;**11**:1185–94.
17. **AGA Institute**. AGA Institute medical position statement on the diagnosis and management of coeliac disease. *Gastroenterology* 2006;**131**:1977–80.
18. **Crowe SE**. In the clinic. Coeliac disease. *Ann Intern Med* 2011;**154**:ITC5-1–15; quiz ITC5-16.
19. **Platt SG**, Kasarda DD. Separation and characterization of -gliadin fractions. *Biochim Biophys Acta* 1971;**243**:407–15.
20. **Koskinen O**, Villanen M, Korponay-Szabo I, *et al*. Oats do not induce systemic or mucosal autoantibody response in children with coeliac disease. *J Pediatr Gastroenterol Nutr* 2009;**48**:559–65.
21. **Katz KD**, Rashtak S, Lahr BD, *et al*. Screening for coeliac disease in a North American population: sequential serology and gastrointestinal symptoms. *Am J Gastroenterol* 2011;**106**:1333–9.
22. **Tursi A**, Elisei W, Giorgetti GM, *et al*. Prevalence of coeliac disease and symptoms in relatives of patients with coeliac disease. *Eur Rev Med Pharmacol Sci* 2010;**14**:567–72.
23. **Freeman HJ**. Risk factors in familial forms of coeliac disease. *World J Gastroenterol* 2010;**16**:1828–31.
24. **Legroux-Gerot I**, Leloire O, Blanckaert F, *et al*. Screening for coeliac disease in patients with osteoporosis. *Joint Bone Spine* 2009;**76**:162–5.
25. **Barker JM**, Liu E. Coeliac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. *Adv Pediatr* 2008;**55**:349–65.
26. **Alzaharani AS**, Al Sheef M. Severe primary hyperparathyroidism masked by asymptomatic coeliac disease. *Endocr Pract* 2008;**14**:347–50.
27. **Ch'ng CL**, Jones MK, Kingham JG. Coeliac disease and autoimmune thyroid disease. *Clin Med Res* 2007;**5**:184–92.
28. **Swigonski NL**, Kuhlenschmidt HL, Bull MJ, *et al*. Screening for coeliac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma. *Pediatrics* 2006;**118**:594–602.
29. **Dube C**, Rostom A, Sy R, *et al*. The prevalence of coeliac disease in average-risk and at-risk Western European populations: a systematic review. *Gastroenterology* 2005;**128**(4 Suppl 1):S57–67.
30. **Kumar V**, Rajadhyaksha M, Wortsman J. Coeliac disease-associated autoimmune endocrinopathies. *Clin Diagn Lab Immunol* 2001;**8**:678–85.
31. **Hoffenberg EJ**, Bao F, Eisenbarth GS, *et al*. Transglutaminase antibodies in children with a genetic risk for coeliac disease. *J Pediatr* 2000;**137**:356–60.
32. **Lorini R**, Scaramuzza A, Vitali L, *et al*. Clinical aspects of coeliac disease in children with insulin-dependent diabetes mellitus. *J Pediatr Endocrinol Metab* 1996;**9**(Suppl 1):101–11.
33. **Stewart J**. Asymptomatic coeliac disease in adults. *Ir Med J* 1974;**67**:415–16.
34. **Marine M**, Fernandez-Banars F, Alsina M, *et al*. Impact of mass screening for gluten-sensitive enteropathy in working population. *World J Gastroenterol* 2009;**15**:1331–8.
35. **Maki M**, Kallonen K, Lahdeaho ML, *et al*. Changing pattern of childhood coeliac disease in Finland. *Acta Paediatr Scand* 1988;**77**:408–12.
36. **Ludvigsson JF**, Ansved P, Falth-Magnusson K, *et al*. Symptoms and signs have changed in Swedish children with coeliac disease. *J Pediatr Gastroenterol Nutr* 2004;**38**:181–6.
37. **Rampertab SD**, Pooran N, Brar P, *et al*. Trends in the presentation of coeliac disease. *Am J Med* 2006;**119**:e9–14.
38. **Corazza GR**, Valentini RA, Andreani ML, *et al*. Subclinical coeliac disease is a frequent cause of iron-deficiency anaemia. *Scand J Gastroenterol* 1995;**30**:153–6.
39. **Hin H**, Bird G, Fisher P, *et al*. Coeliac disease in primary care: case finding study. *BMJ* 1999;**318**:164–7.
40. **Unsworth DJ**, Lock RJ, Harvey RF. Improving the diagnosis of coeliac disease in anaemic women. *Br J Haematol* 2000;**111**:898–901.

## Coeliac disease

41. **Siniscalchi M**, Iovino P, Tortora R, *et al*. Fatigue in adult coeliac disease. *Aliment Pharmacol Ther* 2005;**22**:489–94.
42. **Sanders DS**, Evans KE, Hadjivassiliou M. Fatigue in primary care. Test for coeliac disease first? *BMJ* 2010;**341**:c5161.
43. **van der Windt DA**, Jellema P, Mulder CJ, *et al*. Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. *JAMA* 2010;**303**:1738–46.
44. **Nachman F**, Vazquez H, Gonzalez A, *et al*. Gastroesophageal reflux symptoms in patients with celiac disease and the effects of a gluten-free diet. *Clin Gastroenterol Hepatol* 2011;**9**:214–19.
45. **Sanders DS**, Carter MJ, Hurlstone DP, *et al*. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. *Lancet* 2001;**358**:1504–8.
46. **Ford AC**, Chey WD, Talley NJ, *et al*. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. *Arch Intern Med* 2009;**169**:651–8.
47. **Volta U**, De Franceschi L, Lari F, *et al*. Coeliac disease hidden by cryptogenic hypertransaminasaemia. *Lancet* 1998;**352**:26–9.
48. **Franzese A**, Iannucci MP, Valerio G, *et al*. Atypical celiac disease presenting as obesity-related liver dysfunction. *J Pediatr Gastroenterol Nutr* 2001;**33**:329–32.
49. **Puri AS**, Garg S, Monga R, *et al*. Spectrum of atypical celiac disease in North Indian children. *Indian Pediatr* 2004;**41**:822–7.
50. **Elfstrom P**, Montgomery SM, Kampe O, *et al*. Risk of thyroid disease in individuals with celiac disease. *J Clin Endocrinol Metab* 2008;**93**:3915–21.
51. **Lionetti E**, Francavilla R, Pavone P, *et al*. The neurology of coeliac disease in childhood: what is the evidence? A systematic review and meta-analysis. *Dev Med Child Neurol* 2010;**52**:700–7.
52. **Hadjivassiliou M**, Grunewald RA, Kandler RH, *et al*. Neuropathy associated with gluten sensitivity. *J Neurol Neurosurg Psychiatry* 2006;**77**:1262–6.
53. **Ludvigsson JF**, Olsson T, Ekbohm A, *et al*. A population-based study of coeliac disease, neurodegenerative and neuroinflammatory diseases. *Aliment Pharmacol Ther* 2007;**25**:1317–27.
54. **Ciacchi C**, Iavarone A, Mazzacca G, *et al*. Depressive symptoms in adult coeliac disease. *Scand J Gastroenterol* 1998;**33**:247–50.
55. **Hadjivassiliou M**, Sanders DS, Woodroffe N, *et al*. Gluten ataxia. *Cerebellum* 2008;**7**:494–8.
56. **Zugna D**, Richiardi L, Akre O, *et al*. A nationwide population-based study to determine whether coeliac disease is associated with infertility. *Gut* 2010;**59**:1471–5.
57. **Ciacchi C**, Cirillo M, Auremma G, *et al*. Celiac disease and pregnancy outcome. *Am J Gastroenterol* 1996;**91**:718–22.
58. **Santonicola A**, Iovino P, Cappello C, *et al*. From menarche to menopause: the fertile life span of celiac women. *Menopause* 2011;**18**:1125–30.
59. **Martinelli D**, Fortunato F, Tafuri S, *et al*. Reproductive life disorders in Italian celiac women. A case-control study. *BMC Gastroenterol* 2010;**10**:89.
60. **Corazza GR**, Andreani ML, Ventura N, *et al*. Celiac disease and alopecia areata: report of a new association. *Gastroenterology* 1995;**109**:1333–7.
61. **Ferguson MM**, Wray D, Carmichael HA, *et al*. Coeliac disease associated with recurrent aphthae. *Gut* 1980;**21**:223–6.
62. **Cheng J**, Malahias T, Brar P, *et al*. The association between celiac disease, dental enamel defects, and aphthous ulcers in a United States cohort. *J Clin Gastroenterol* 2010;**44**:191–4.
63. **Ludvigsson JF**, Lindelof B, Zingone F, *et al*. Psoriasis in a nationwide cohort study of patients with celiac disease. *J Invest Dermatol* 2011;**131**:2010–16.
64. **Pastore L**, Lo Muzio L, Serpico R. Atrophic glossitis leading to the diagnosis of celiac disease. *N Engl J Med* 2007;**356**:2547.
65. **Zone JJ**. Skin manifestations of celiac disease. *Gastroenterology* 2005;**128** (4 Suppl 1):S87–91.
66. **Collin P**, Korpela M, Hallstrom O, *et al*. Rheumatic complaints as a presenting symptom in patients with coeliac disease. *Scand J Rheumatol* 1992;**21**:20–3.
67. **Logan RF**, Tucker G, Rifkind EA, *et al*. Changes in clinical features of coeliac disease in adults in Edinburgh and the Lothians 1960–79. *Br Med J (Clin Res Ed)* 1983;**286**:95–7.
68. **Farrell RJ**, Kelly CP. Diagnosis of celiac sprue. *Am J Gastroenterol* 2001;**96**:3237–46.
69. **Wahab PJ**, Meijer JW, Goerres MS, *et al*. Coeliac disease: changing views on gluten-sensitive enteropathy. *Scand J Gastroenterol Suppl* 2002;**236**:60–5.
70. **Lo W**, Sano K, Lebwohl B, *et al*. Changing presentation of adult celiac disease. *Dig Dis Sci* 2003;**48**:395–8.
71. **Mulder CJ**, Cellier C. Coeliac disease: changing views. *Best Pract Res Clin Gastroenterol* 2005;**19**:313–21.
72. **Dewar DH**, Ciclitira PJ. Clinical features and diagnosis of celiac disease. *Gastroenterology* 2005;**128**(4 Suppl 1):S19–24.
73. **Fasano A**, Catassi C. Coeliac disease in children. *Best Pract Res Clin Gastroenterol* 2005;**19**:467–78.
74. **Nachman F**, Mauro E, Vazquez H, *et al*. Quality of life in celiac disease patients: prospective analysis on the importance of clinical severity at diagnosis and the impact of treatment. *Dig Liver Dis* 2009;**41**:15–25.
75. **Ascher H**, Holm K, Kristiansson B, *et al*. Different features of coeliac disease in two neighbouring countries. *Arch Dis Child* 1993;**69**:375–80.
76. **Bardella MT**, Fredella C, Saladino V, *et al*. Gluten intolerance: gender- and age-related differences in symptoms. *Scand J Gastroenterol* 2005;**40**:15–19.
77. **McGowan KE**, Castiglione DA, Butzner JD. The changing face of childhood celiac disease in North America: impact of serological testing. *Pediatrics* 2009;**124**:1572–8.
78. **Visakorpi JK**, Maki M. Changing clinical features of coeliac disease. *Acta Paediatr Suppl* 1994;**83**:10–13.
79. **Fasano A**. Clinical presentation of celiac disease in the pediatric population. *Gastroenterology* 2005;**128**(4 Suppl 1):S68–73.
80. **Meloni G**, Dore A, Fanciulli G, *et al*. Subclinical coeliac disease in schoolchildren from northern Sardinia. *Lancet* 1999;**353**:37.
81. **Corazza GR**, Frisoni M, Treggiari EA, *et al*. Subclinical celiac sprue. Increasing occurrence and clues to its diagnosis. *J Clin Gastroenterol* 1993;**16**:16–21.
82. **Bottaro G**, Cataldo F, Rotolo N, *et al*. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. *Am J Gastroenterol* 1999;**94**:691–6.
83. **Moreno ML**, Vazquez H, Mazure R, *et al*. Stratification of bone fracture risk in patients with celiac disease. *Clin Gastroenterol Hepatol* 2004;**2**:127–34.
84. **Baccini F**, Spiriti MA, Vannella L, *et al*. Unawareness of gastrointestinal symptomatology in adult coeliac patients with unexplained iron-deficiency anaemia presentation. *Aliment Pharmacol Ther* 2006;**23**:915–21.
85. **Koskinen O**, Collin P, Korponay-Szabo I, *et al*. Gluten-dependent small bowel mucosal transglutaminase 2-specific IgA deposits in overt and mild enteropathy coeliac disease. *J Pediatr Gastroenterol Nutr* 2008;**47**:436–42.
86. **Tjon JM**, van Bergen J, Koning F. Celiac disease: how complicated can it get? *Immunogenetics* 2010;**62**:641–51.
87. **Ciacchi C**, Mairi L, Russo I, *et al*. Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/in vitro pilot study. *Clin Exp Pharmacol Physiol* 2009;**36**:1170–6.
88. **West J**, Logan RF, Hill PG, *et al*. The iceberg of celiac disease: what is below the waterline? *Clin Gastroenterol Hepatol* 2007;**5**:59–62.
89. **Schuppan D**, Kelly CP, Krauss N. Monitoring non-responsive patients with celiac disease. *Gastrointest Endosc Clin N Am* 2006;**16**:593–603.
90. **Holtmeier W**, Caspary WF. Celiac disease. *Orphanet J Rare Dis* 2006;**1**:3.
91. **Lahdeaho ML**, Kaukinen K, Collin P, *et al*. Celiac disease: from inflammation to atrophy: a long-term follow-up study. *J Pediatr Gastroenterol Nutr* 2005;**41**:44–8.
92. **Karnam US**, Felder LR, Raskin JB. Prevalence of occult celiac disease in patients with iron-deficiency anemia: a prospective study. *South Med J* 2004;**97**:30–4.
93. **Barera G**, Bonfanti R, Viscardi M, *et al*. Occurrence of celiac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study. *Pediatrics* 2002;**109**:833–8.
94. **Volta U**, Bellentani S, Bianchi FB, *et al*. High prevalence of celiac disease in Italian general population. *Dig Dis Sci* 2001;**46**:1500–5.
95. **Ciacchi C**, Cirillo M, Giorgetti G, *et al*. Low plasma cholesterol: a correlate of nondiagnosed celiac disease in adults with hypochromic anemia. *Am J Gastroenterol* 1999;**94**:1888–91.
96. **Falth-Magnusson K**, Franzen L, Jansson G, *et al*. Infant feeding history shows distinct differences between Swedish celiac and reference children. *Pediatr Allergy Immunol* 1996;**7**:1–5.
97. **Doherty M**, Barry RE. Gluten-induced mucosal changes in subjects without overt small-bowel disease. *Lancet* 1981;**1**:517–20.
98. **Ciacchi C**, Cirillo M, Mellone M, *et al*. Hypocalciuria in overt and subclinical celiac disease. *Am J Gastroenterol* 1995;**90**:1480–4.
99. **Polanco I**, Mearin ML, Larrauri J, *et al*. Effect of gluten supplementation in healthy siblings of children with celiac disease. *Gastroenterology* 1987;**92**:678–81.
100. **Caputo M**, Brizzolaro R, Schiavo M, *et al*. Occurrence of overt celiac disease in the elderly following total thyroidectomy. *J Endocrinol Invest* 2006;**29**:831–3.
101. **Roshan B**, Leffler DA, Jamma S, *et al*. The incidence and clinical spectrum of refractory celiac disease in a North American referral center. *Am J Gastroenterol* 2011;**106**:923–8.
102. **van de Water JM**, Cillessen SA, Visser OJ, *et al*. Enteropathy associated T-cell lymphoma and its precursor lesions. *Best Pract Res Clin Gastroenterol* 2010;**24**:43–56.
103. **Walker MM**, Murray JA. An update in the diagnosis of coeliac disease. *Histopathology* 2011;**59**:166–79.
104. **Rubio-Tapia A**, Murray JA. Classification and management of refractory coeliac disease. *Gut* 2010;**59**:547–57.
105. **Ho-Yen C**, Chang F, van der Walt J, *et al*. Recent advances in refractory coeliac disease: a review. *Histopathology* 2009;**54**:783–95.
106. **Rubio-Tapia A**, Kelly DG, Lahr BD, *et al*. Clinical staging and survival in refractory celiac disease: a single center experience. *Gastroenterology* 2009;**136**:99–107; quiz 352–3.
107. **Malamut G**, Afchain P, Verkarre V, *et al*. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. *Gastroenterology* 2009;**136**:81–90.
108. **Verbeek WH**, Goerres MS, von Blomberg BM, *et al*. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. *Clin Immunol* 2008;**126**:48–56.
109. **Al-Toma A**, Verbeek WH, Mulder CJ. Update on the management of refractory coeliac disease. *J Gastrointest Liver Dis* 2007;**16**:57–63.
110. **Maurino E**, Niveloni S, Chernavsky AC, *et al*. Clinical characteristics and long-term outcome of patients with refractory sprue diagnosed at a single institution. *Acta Gastroenterol Latinoam* 2006;**36**:10–22.



111. **Daum S**, Cellier C, Mulder CJ. Refractory coeliac disease. *Best Pract Res Clin Gastroenterol* 2005;**19**:413–24.
112. **Biagi F**, Corazza GR. Defining gluten refractory enteropathy. *Eur J Gastroenterol Hepatol* 2001;**13**:561–5.
113. **Daum S**, Weiss D, Hummel M, *et al*. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. *Gut* 2001;**49**:804–12.
114. **United European Gastroenterology**. When is a coeliac a coeliac? Report of a working group of the United European Gastroenterology Week in Amsterdam, 2001. *Eur J Gastroenterol Hepatol* 2001;**13**:1123–8.
115. **Cellier C**, Delabesse E, Helmer C, *et al*. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. *Lancet* 2000;**356**:203–8.
116. **Patey-Mariaud De Serre N**, Cellier C, Jabri B, *et al*. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. *Histopathology* 2000;**37**:70–7.
117. **Bagdi E**, Diss TC, Munson P, *et al*. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory coeliac disease constitute a neoplastic population. *Blood* 1999;**94**:260–4.
118. **Cellier C**, Patey N, Mauvieux L, *et al*. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. *Gastroenterology* 1998;**114**:471–81.
119. **Fine KD**, Meyer RL, Lee EL. The prevalence and causes of chronic diarrhea in patients with coeliac sprue treated with a gluten-free diet. *Gastroenterology* 1997;**112**:1830–8.
120. **Vahedi K**, Mascart F, Mary JY, *et al*. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult coeliac disease. *Am J Gastroenterol* 2003;**98**:1079–87.
121. **Leffler DA**, Dennis M, Hyett B, *et al*. Etiologies and predictors of diagnosis in nonresponsive coeliac disease. *Clin Gastroenterol Hepatol* 2007;**5**:445–50.
122. **Fan X**, Sellin JH. Review article: small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. *Aliment Pharmacol Ther* 2009;**29**:1069–77.
123. **Abdulkarim AS**, Burgart LJ, See J, *et al*. Etiology of nonresponsive coeliac disease: results of a systematic approach. *Am J Gastroenterol* 2002;**97**:2016–21.
124. **Johnston SD**, Watson RG, Middleton D, *et al*. Genetic, morphometric and immunohistochemical markers of latent coeliac disease. *Eur J Gastroenterol Hepatol* 1999;**11**:1283–8.
125. **Meloni GF**, Dessole S, Vargiu N, *et al*. The prevalence of coeliac disease in infertility. *Hum Reprod* 1999;**14**:2759–61.
126. **Anon**. National Institutes of Health Consensus Development Conference statement on coeliac disease, June 28–30, 2004. *Gastroenterology* 2005;**128**(4 Suppl 1):S1–9.
127. **Ludvigsson JF**, Brandt L, Montgomery SM. Symptoms and signs in individuals with serology positive for coeliac disease but normal mucosa. *BMC Gastroenterol* 2009;**9**:57.
128. **Ludvigsson JF**, Montgomery SM, Ekbohm A, *et al*. Small-intestinal histopathology and mortality risk in coeliac disease. *JAMA* 2009;**302**:1171–8.
129. **Basso D**, Guariso G, Fogar P, *et al*. Antibodies against synthetic deamidated gliadin peptides for coeliac disease diagnosis and follow-up in children. *Clin Chem* 2009;**55**:150–7.
130. **Corazza GR**, Andreani ML, Biagi F, *et al*. Clinical, pathological, and antibody pattern of latent coeliac disease: report of three adult cases. *Am J Gastroenterol* 1996;**91**:2203–7.
131. **Ferguson A**, Blackwell JN, Barnetson RS. Effects of additional dietary gluten on the small-intestinal mucosa of volunteers and of patients with dermatitis herpetiformis. *Scand J Gastroenterol* 1987;**22**:543–9.
132. **Murray IA**, Smith JA, Coupland K, *et al*. Intestinal disaccharidase deficiency without villous atrophy may represent early coeliac disease. *Scand J Gastroenterol* 2001;**36**:163–8.
133. **Kurppa K**, Ashorn M, Iltanen S, *et al*. Coeliac disease without villous atrophy in children: a prospective study. *J Pediatr* 2010;**157**:373–80, 380.e1.
134. **Kurppa K**, Collin P, Viljamaa M, *et al*. Diagnosing mild enteropathy coeliac disease: a randomized, controlled clinical study. *Gastroenterology* 2009;**136**:816–23.
135. **Freeman HJ**, Chiu BK. Multifocal small bowel lymphoma and latent coeliac sprue. *Gastroenterology* 1986;**90**:1992–7.
136. **Hovdenak N**, Hovlid E, Aksnes L, *et al*. High prevalence of asymptomatic coeliac disease in Norway: a study of blood donors. *Eur J Gastroenterol Hepatol* 1999;**11**:185–7.
137. **Moayyedi P**, O'Mahony S, Jackson P, *et al*. Small intestine in lymphocytic and collagenous colitis: mucosal morphology, permeability, and secretory immunity to gliadin. *J Clin Pathol* 1997;**50**:527–9.
138. **Biagi F**, Luinetti O, Campanella J, *et al*. Intraepithelial lymphocytes in the villous tip: do they indicate potential coeliac disease? *J Clin Pathol* 2004;**57**:835–9.
139. **Arranz E**, Bode J, Kingstone K, *et al*. Intestinal antibody pattern of coeliac disease: association with gamma/delta T cell receptor expression by intraepithelial lymphocytes, and other indices of potential coeliac disease. *Gut* 1994;**35**:476–82.
140. **Maki M**, Holm K, Collin P, *et al*. Increase in gamma/delta T cell receptor bearing lymphocytes in normal small bowel mucosa in latent coeliac disease. *Gut* 1991;**32**:1412–14.
141. **Maki M**, Huuopponen T, Holm K, *et al*. Seroconversion of reticulin autoantibodies predicts coeliac disease in insulin dependent diabetes mellitus. *Gut* 1995;**36**:239–42.
142. **Ferguson A**, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease—active, silent, latent, potential. *Gut* 1993;**34**:150–1.
143. **Lebwohl B**, Kapel RC, Neugut AI, *et al*. Adherence to biopsy guidelines increases coeliac disease diagnosis. *Gastrointest Endosc* 2011;**74**:103–9.
144. **Hummel S**, Hummel M, Banholzer J, *et al*. Development of autoimmunity to transglutaminase C in children of patients with type 1 diabetes: relationship to islet autoantibodies and infant feeding. *Diabetologia* 2007;**50**:390–4.
145. **Liu E**, Li M, Emery L, *et al*. Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood coeliac disease. *J Pediatr Gastroenterol Nutr* 2007;**45**:293–300.
146. **Simmons JH**, Klingensmith GJ, McFann K, *et al*. Impact of coeliac autoimmunity on children with type 1 diabetes. *J Pediatr* 2007;**150**:461–6.
147. **Diniz-Santos DR**, Brandao F, Adan L, *et al*. Bone mineralization in young patients with type 1 diabetes mellitus and screening-identified evidence of coeliac disease. *Dig Dis Sci* 2008;**53**:1240–5.
148. **De Block CE**, De Leeuw IH, Vertommen JJ, *et al*. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. *Clin Exp Immunol* 2001;**126**:236–41.
149. **Catassi C**, Kryszak D, Bhatti B, *et al*. Natural history of coeliac disease autoimmunity in a USA cohort followed since 1974. *Ann Med* 2010;**42**:530–8.
150. **Stene LC**, Honeyman MC, Hoffenberg EJ, *et al*. Rotavirus infection frequency and risk of coeliac disease autoimmunity in early childhood: a longitudinal study. *Am J Gastroenterol* 2006;**101**:2333–40.
151. **Norris JM**, Barriga K, Hoffenberg EJ, *et al*. Risk of coeliac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. *JAMA* 2005;**293**:2343–51.
152. **Dezsofi A**, Szebeni B, Hermann CS, *et al*. Frequencies of genetic polymorphisms of TLR4 and CD14 and of HLA-DQ genotypes in children with coeliac disease, type 1 diabetes mellitus, or both. *J Pediatr Gastroenterol Nutr* 2008;**47**:283–7.
153. **Fasano A**. Coeliac disease—how to handle a clinical chameleon. *N Engl J Med* 2003;**348**:2568–70.
154. **van Heel DA**, Franke L, Hunt KA, *et al*. A genome-wide association study for coeliac disease identifies risk variants in the region harboring IL2 and IL21. *Nat Genet* 2007;**39**:827–9.
155. **Newnham ED**. Does gluten cause gastrointestinal symptoms in subjects without coeliac disease? *J Gastroenterol Hepatol* 2011;**26**(Suppl 3):132–4.
156. **Biesiekierski JR**, Newnham ED, Irving PM, *et al*. Gluten causes gastrointestinal symptoms in subjects without coeliac disease: a double-blind randomized placebo-controlled trial. *Am J Gastroenterol* 2011;**106**:508–14; quiz 515. doi:10.1038/ajg.2010.487
157. **Bizzaro N**, Tozzoli R, Villalta D, *et al*. Cutting-edge issues in coeliac disease and in gluten intolerance. *Clin Rev Allergy Immunol*. Published Online First: 23 December 2010.
158. **Poloni N**, Vender S, Bolla E, *et al*. Gluten encephalopathy with psychiatric onset: case report. *Clin Pract Epidemiol Ment Health* 2009;**5**:16.
159. **Cascella NG**, Kryszak D, Bhatti B, *et al*. Prevalence of coeliac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. *Schizophr Bull* 2011;**37**:94–100.
160. **Ozdemir O**, Mete E, Catal F, *et al*. Food intolerances and eosinophilic esophagitis in childhood. *Dig Dis Sci* 2009;**54**:8–14.
161. **Llorente-Alonso MJ**, Fernandez-Acenero MJ, Sebastian M. Gluten intolerance: sex and age-related features. *Can J Gastroenterol* 2006;**20**:719–22.
162. **Humbert P**, Pelletier F, Dreno B, *et al*. Gluten intolerance and skin diseases. *Eur J Dermatol* 2006;**16**:4–11.
163. **Kalaydjian AE**, Eaton W, Cascella N, *et al*. The gluten connection: the association between schizophrenia and coeliac disease. *Acta Psychiatr Scand* 2006;**113**:82–90.
164. **Sbattero D**, Ventura A, Tommasini A, *et al*. Cryptic gluten intolerance in type 1 diabetes: identifying suitable candidates for a gluten free diet. *Gut* 2006;**55**:133–4.
165. **Helms S**. Coeliac disease and gluten-associated diseases. *Altern Med Rev* 2005;**10**:172–92.
166. **Gobbi G**. Coeliac disease, epilepsy and cerebral calcifications. *Brain Dev* 2005;**27**:189–200.
167. **Volta U**, De Giorgio R, Petrolini N, *et al*. Clinical findings and anti-neuronal antibodies in coeliac disease with neurological disorders. *Scand J Gastroenterol* 2002;**37**:1276–81.
168. **Leggio L**, Abenavoli L, D'Angelo C, *et al*. Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients. *Aliment Pharmacol Ther* 2004;**20**:821–2; author reply 822.
169. **Sardy M**, Karpati S, Merkl B, *et al*. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. *J Exp Med* 2002;**195**:747–57.
170. **Hadjivassiliou M**, Grunewald RA, Chattopadhyay AK, *et al*. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. *Lancet* 1998;**352**:1582–5.
171. **Troncone R**, Jabri B. Coeliac disease and gluten sensitivity. *J Intern Med* 2011;**269**:582–90.
172. **Massari S**, Liso M, De Santis L, *et al*. Occurrence of nonceliac gluten sensitivity in patients with allergic disease. *Int Arch Allergy Immunol* 2011;**155**:389–94.
173. **Sapone A**, Lammers KM, Casolaro V, *et al*. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: coeliac disease and gluten sensitivity. *BMC Med* 2011;**9**:23.
174. **Sapone A**, Lammers KM, Mazzarella G, *et al*. Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy coeliac disease. *Int Arch Allergy Immunol* 2010;**152**:75–80.

## Coeliac disease

175. **Verdu EF**. Editorial: Can gluten contribute to irritable bowel syndrome? *Am J Gastroenterol* 2011;**106**:516–18.
176. **de Magistris L**, Familiari V, Pascotto A, *et al*. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. *J Pediatr Gastroenterol Nutr* 2010;**51**:418–24.
177. **Signer E**, Burgin-Wolff A, Berger R, *et al*. Antibodies to gliadin as a screening test for coeliac disease. A prospective study. *Helv Paediatr Acta* 1979;**34**:41–52.
178. **O'Farrelly C**, Kelly J, Hekkens W, *et al*. Alpha gliadin antibody levels: a serological test for coeliac disease. *Br Med J (Clin Res Ed)* 1983;**286**:2007–10.
179. **Leffler DA**, Schuppan D. Update on serologic testing in celiac disease. *Am J Gastroenterol* 2010;**105**:2520–4.
180. **Lagerqvist C**, Dahlbom I, Hansson T, *et al*. Antigliadin immunoglobulin A best in finding celiac disease in children younger than 18 months of age. *J Pediatr Gastroenterol Nutr* 2008;**47**:428–35.
181. **Schwartz E**, Kahlenberg F, Sack U, *et al*. Serologic assay based on gliadin-related nonapeptides as a highly sensitive and specific diagnostic aid in celiac disease. *Clin Chem* 2004;**50**:2370–5.
182. **Osman AA**, Uhlig HH, Valdes I, *et al*. A monoclonal antibody that recognizes a potential coeliac-toxic repetitive pentapeptide epitope in gliadins. *Eur J Gastroenterol Hepatol* 2001;**13**:1189–93.
183. **Mendez E**, Vela C, Immer U, *et al*. Report of a collaborative trial to investigate the performance of the R5 enzyme linked immunoassay to determine gliadin in gluten-free food. *Eur J Gastroenterol Hepatol* 2005;**17**:1053–63.
184. **Burgin-Wolff A**, Gaze H, Hadziselimovic F, *et al*. Antigliadin and antiendomysium antibody determination for coeliac disease. *Arch Dis Child* 1991;**66**:941–7.
185. **Dieterich W**, Ehnis T, Bauer M, *et al*. Identification of tissue transglutaminase as the autoantigen of celiac disease. *Nat Med* 1997;**3**:797–801.
186. **Sulkanen S**, Halttunen T, Laurila K, *et al*. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. *Gastroenterology* 1998;**115**:1322–8.
187. **Dieterich W**, Laag E, Schopper H, *et al*. Autoantibodies to tissue transglutaminase as predictors of celiac disease. *Gastroenterology* 1998;**115**:1317–21.
188. **Hadithi M**, von Blomberg BM, Crusius JB, *et al*. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. *Ann Intern Med* 2007;**147**:294–302.
189. **Cooke WT**, Smith WT. Neurological disorders associated with adult coeliac disease. *Brain* 1966;**89**:683–722.
190. **Hadjivassiliou M**, Sanders DS, Grunewald RA, *et al*. Gluten sensitivity: from gut to brain. *Lancet Neurol* 2010;**9**:318–30.
191. **Burk K**, Farecki ML, Lamprecht G, *et al*. Neurological symptoms in patients with biopsy proven celiac disease. *Mov Disord* 2009;**24**:2358–62.
192. **Hadjivassiliou M**, Aeschlimann P, Strigun A, *et al*. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. *Ann Neurol* 2008;**64**:332–43.
193. **Boscolo S**, Sarich A, Lorenzon A, *et al*. Gluten ataxia: passive transfer in a mouse model. *Ann N Y Acad Sci* 2007;**1107**:319–28.
194. **Ihara M**, Makino F, Sawada H, *et al*. Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. *Intern Med* 2006;**45**:135–40.
195. **Hadjivassiliou M**, Maki M, Sanders DS, *et al*. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. *Neurology* 2006;**66**:373–7.
196. **Hadjivassiliou M**, Davies-Jones GA, Sanders DS, *et al*. Dietary treatment of gluten ataxia. *J Neurol Neurosurg Psychiatry* 2003;**74**:1221–4.
197. **Abele M**, Schols L, Schwartz S, *et al*. Prevalence of anti-gliadin antibodies in ataxia patients. *Neurology* 2003;**60**:1674–5.
198. **Hadjivassiliou M**, Grunewald R, Sharrack B, *et al*. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. *Brain* 2003;**126**:685–91.
199. **Luostarinen LK**, Collin PO, Peraaho MJ, *et al*. Coeliac disease in patients with cerebellar ataxia of unknown origin. *Ann Med* 2001;**33**:445–9.
200. **van der Meer JB**. Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study. *Br J Dermatol* 1969;**81**:493–503.
201. **Meyer LJ**, Carioto L, Zone JJ. Dermatitis herpetiformis: extraction of intact IgA from granular deposits in dermal papillae. *J Invest Dermatol* 1987;**88**:559–63.
202. **Zone JJ**, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. *Arch Dermatol* 1996;**132**:912–18.
203. **Fry L**, Keir P, McMinn RM, *et al*. Small-intestinal structure and function and haematological changes in dermatitis herpetiformis. *Lancet* 1967;**2**:729–33.
204. **Fry L**, Seah PP, Harper PG, *et al*. The small intestine in dermatitis herpetiformis. *J Clin Pathol* 1974;**27**:817–24.
205. **Bolotin D**, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. *J Am Acad Dermatol* 2011;**64**:1017–24; quiz 1025–6.
206. **Fry L**, Seah PP, Riches DJ, *et al*. Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. *Lancet* 1973;**1**:288–91.
207. **Leonard J**, Haffenden G, Tucker W, *et al*. Gluten challenge in dermatitis herpetiformis. *N Engl J Med* 1983;**308**:816–19.
208. **Reunala T**, Blomqvist K, Tarpila S, *et al*. Gluten-free diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients. *Br J Dermatol* 1977;**97**:473–80.
209. **Garioch JJ**, Lewis HM, Sargent SA, *et al*. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. *Br J Dermatol* 1994;**131**:541–5.
210. **Smith JB**, Tulloch JE, Meyer LJ, *et al*. The incidence and prevalence of dermatitis herpetiformis in Utah. *Arch Dermatol* 1992;**128**:1608–10.
211. **Hardman CM**, Garioch JJ, Leonard JN, *et al*. Absence of toxicity of oats in patients with dermatitis herpetiformis. *N Engl J Med* 1997;**337**:1884–7.
212. **Collin P**, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. *Am J Clin Dermatol* 2003;**4**:13–20.
213. **Caproni M**, Antiga E, Melani L, *et al*. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. *J Eur Acad Dermatol Venereol* 2009;**23**:633–8.
214. **Collin P**, Pukkala E, Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. *Gut* 1996;**38**:528–30.



## The Oslo definitions for coeliac disease and related terms

Jonas F Ludvigsson, Daniel A Leffler, Julio C Bai, et al.

*Gut* 2013 62: 43-52 originally published online February 16, 2012  
doi: 10.1136/gutjnl-2011-301346

---

Updated information and services can be found at:  
<http://gut.bmj.com/content/62/1/43.full.html>

---

|                               |  |
|-------------------------------|--|
|                               | <i>These include:</i>  |
| <b>Data Supplement</b>        | "Supplementary Data"<br><a href="http://gut.bmj.com/content/suppl/2012/02/15/gutjnl-2011-301346.DC1.html">http://gut.bmj.com/content/suppl/2012/02/15/gutjnl-2011-301346.DC1.html</a>  |
| <b>References</b>             | This article cites 213 articles, 42 of which can be accessed free at:<br><a href="http://gut.bmj.com/content/62/1/43.full.html#ref-list-1">http://gut.bmj.com/content/62/1/43.full.html#ref-list-1</a><br><br>Article cited in:<br><a href="http://gut.bmj.com/content/62/1/43.full.html#related-urls">http://gut.bmj.com/content/62/1/43.full.html#related-urls</a> |
| <b>Email alerting service</b> | Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.   |

---

|                          |   |
|--------------------------|---|
| <b>Topic Collections</b> | Articles on similar topics can be found in the following collections<br><br><a href="#">Editor's choice</a> (69 articles)<br><a href="#">Coeliac disease</a> (453 articles)<br><a href="#">Diarrhoea</a> (558 articles) |
|--------------------------|---|

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>